Cargando…

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing

BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokhandwala, Parvez M., Tseng, Li-Hui, Rodriguez, Erika, Zheng, Gang, Pallavajjalla, Aparna, Gocke, Christopher D., Eshleman, James R., Lin, Ming-Tseh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612071/
https://www.ncbi.nlm.nih.gov/pubmed/31277584
http://dx.doi.org/10.1186/s12885-019-5864-1
_version_ 1783432816160145408
author Lokhandwala, Parvez M.
Tseng, Li-Hui
Rodriguez, Erika
Zheng, Gang
Pallavajjalla, Aparna
Gocke, Christopher D.
Eshleman, James R.
Lin, Ming-Tseh
author_facet Lokhandwala, Parvez M.
Tseng, Li-Hui
Rodriguez, Erika
Zheng, Gang
Pallavajjalla, Aparna
Gocke, Christopher D.
Eshleman, James R.
Lin, Ming-Tseh
author_sort Lokhandwala, Parvez M.
collection PubMed
description BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. KRAS and HRAS were also analyzed to elucidate coexisting BRAF and RAS mutations. BRAF mutations were categorized into class-1 (kinase-activated, codon 600), class-2 (kinase-activated, non-codon 600) and class-3 (kinase-impaired), based on the newly proposed classification scheme. RESULTS: NGS demonstrated high analytic sensitivity. Among 355 mutations detected, variant allele frequencies were 2–5% in 21 (5.9%) mutations and 2–10% in 47 (13%) mutations. Mutations were detected in BRAF (42%), NRAS (25%), KIT (4.9%) and PIK3CA (2.7%). The incidence of class-1, class-2 and class-3 mutations were 33% (26% p.V600E and 6.1% p.V600K), 3.1 and 4.9% respectively. With a broader reportable range of NGS, class-1, class-2 and class-3 mutations accounted for 77, 7.4 and 12% of all BRAF mutations. Class-3 mutations, commonly affecting codons 594, 466 and 467, showed a higher incidence of coexisting RAS mutations, consistent with their RAS-dependent signaling. Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations. CONCLUSION: This study categorizes the range, frequency, coexisting driver mutations and clinical characteristics of the three classes of BRAF mutations in a large cohort of melanomas in a clinical diagnostic setting. Further prospective studies are warranted to elucidate the clinical outcomes and benefits of newly developed targeted therapy in melanoma patients carrying each class of BRAF mutation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5864-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6612071
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66120712019-07-16 Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing Lokhandwala, Parvez M. Tseng, Li-Hui Rodriguez, Erika Zheng, Gang Pallavajjalla, Aparna Gocke, Christopher D. Eshleman, James R. Lin, Ming-Tseh BMC Cancer Research Article BACKGROUND: Analysis of melanomas for actionable mutations has become the standard of care. Recently, a classification scheme has been proposed that categorizes BRAF mutations based on their mechanisms for activation of the MAPK pathway. METHODS: In this analysis BRAF, KIT, NRAS, and PIK3CA mutations were examined by next generation sequencing (NGS) in 446 melanomas in a clinical diagnostic setting. KRAS and HRAS were also analyzed to elucidate coexisting BRAF and RAS mutations. BRAF mutations were categorized into class-1 (kinase-activated, codon 600), class-2 (kinase-activated, non-codon 600) and class-3 (kinase-impaired), based on the newly proposed classification scheme. RESULTS: NGS demonstrated high analytic sensitivity. Among 355 mutations detected, variant allele frequencies were 2–5% in 21 (5.9%) mutations and 2–10% in 47 (13%) mutations. Mutations were detected in BRAF (42%), NRAS (25%), KIT (4.9%) and PIK3CA (2.7%). The incidence of class-1, class-2 and class-3 mutations were 33% (26% p.V600E and 6.1% p.V600K), 3.1 and 4.9% respectively. With a broader reportable range of NGS, class-1, class-2 and class-3 mutations accounted for 77, 7.4 and 12% of all BRAF mutations. Class-3 mutations, commonly affecting codons 594, 466 and 467, showed a higher incidence of coexisting RAS mutations, consistent with their RAS-dependent signaling. Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations. CONCLUSION: This study categorizes the range, frequency, coexisting driver mutations and clinical characteristics of the three classes of BRAF mutations in a large cohort of melanomas in a clinical diagnostic setting. Further prospective studies are warranted to elucidate the clinical outcomes and benefits of newly developed targeted therapy in melanoma patients carrying each class of BRAF mutation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-019-5864-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-05 /pmc/articles/PMC6612071/ /pubmed/31277584 http://dx.doi.org/10.1186/s12885-019-5864-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Lokhandwala, Parvez M.
Tseng, Li-Hui
Rodriguez, Erika
Zheng, Gang
Pallavajjalla, Aparna
Gocke, Christopher D.
Eshleman, James R.
Lin, Ming-Tseh
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title_full Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title_fullStr Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title_full_unstemmed Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title_short Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
title_sort clinical mutational profiling and categorization of braf mutations in melanomas using next generation sequencing
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612071/
https://www.ncbi.nlm.nih.gov/pubmed/31277584
http://dx.doi.org/10.1186/s12885-019-5864-1
work_keys_str_mv AT lokhandwalaparvezm clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT tsenglihui clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT rodriguezerika clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT zhenggang clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT pallavajjallaaparna clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT gockechristopherd clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT eshlemanjamesr clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing
AT linmingtseh clinicalmutationalprofilingandcategorizationofbrafmutationsinmelanomasusingnextgenerationsequencing